 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- ||||| felcisetrag (TAK-954) / Theravance Biopharma
New P1/2 trial: A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance (clinicaltrials.gov) - Sep 26, 2013
P1/2, N=60, Recruiting, Sponsor: Theravance, Inc.
- felcisetrag (TAK-954) / Theravance Biopharma
Enrollment change: A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects (clinicaltrials.gov) - Jan 20, 2013
P1, N=16, Completed, Sponsor: Theravance, Inc.
N=32 --> 16
- | felcisetrag (TAK-954) / Theravance Biopharma
Trial completion: A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects (clinicaltrials.gov) - Jan 20, 2013
P1, N=16, Completed, Sponsor: Theravance, Inc.
N=32 --> 16 Not yet recruiting --> Completed
- | felcisetrag (TAK-954) / Theravance Biopharma
New P1 trial: A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects (clinicaltrials.gov) - Jul 17, 2012
P1, N=16, Completed, Sponsor: Theravance, Inc.